Trovafloxacin Mesylate (BioDeep_00000794650)
代谢物信息卡片
Trovafloxacin Mesylate
化学式: C21H19F3N4O6S (512.0977350000001)
中文名称: 曲伐沙星甲磺酸盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CS(=O)(=O)O.C1C2C(C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
InChI: 1H3,(H,2,3,4)/t10-,11+,16+
描述信息
A methanesulfonate (mesylate) salt prepared from equimolar amounts of trovafloxacin and methanesulfonic acid. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones
C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
D004791 - Enzyme Inhibitors
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:77568
- KEGGdrug: D02123
- PubChem: 62960
- ChEMBL: CHEMBL1200779
- CAS: 147059-75-4
- MetaboLights: MTBLC77568
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Giulio Giustarini, Nienke Vrisekoop, Laura Kruijssen, Laura Wagenaar, Selma van Staveren, Manon van Roest, Rob Bleumink, Marianne Bol-Schoenmakers, Richard J Weaver, Leo Koenderman, Joost Smit, Raymond Pieters. Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement.
Toxicological sciences : an official journal of the Society of Toxicology.
2019 02; 167(2):385-396. doi:
10.1093/toxsci/kfy244. [PMID: 30247740] - Yu-Hsin Chiu, Xueyao Jin, Christopher B Medina, Susan A Leonhardt, Volker Kiessling, Brad C Bennett, Shaofang Shu, Lukas K Tamm, Mark Yeager, Kodi S Ravichandran, Douglas A Bayliss. A quantized mechanism for activation of pannexin channels.
Nature communications.
2017 01; 8(?):14324. doi:
10.1038/ncomms14324. [PMID: 28134257] - Nuggehally R Srinivas. Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion.
Xenobiotica; the fate of foreign compounds in biological systems.
2016 Sep; 46(9):784-92. doi:
10.3109/00498254.2015.1121554. [PMID: 26711252] - Adnan H Mahmood, Xin Liu, Jeffrey E Grice, Gregory A Medley, Michael S Roberts. Using deconvolution to understand the mechanism for variable plasma concentration-time profiles after intramuscular injection.
International journal of pharmaceutics.
2015 Mar; 481(1-2):71-8. doi:
10.1016/j.ijpharm.2015.01.046. [PMID: 25636300] - Kyle L Poulsen, Jesus Olivero-Verbel, Kevin M Beggs, Patricia E Ganey, Robert A Roth. Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.
The Journal of pharmacology and experimental therapeutics.
2014 Jul; 350(1):164-70. doi:
10.1124/jpet.114.214189. [PMID: 24817034] - Kyle L Poulsen, Ryan P Albee, Patricia E Ganey, Robert A Roth. Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.
The Journal of pharmacology and experimental therapeutics.
2014 May; 349(2):185-91. doi:
10.1124/jpet.113.211276. [PMID: 24525298] - Ivan K H Poon, Yu-Hsin Chiu, Allison J Armstrong, Jason M Kinchen, Ignacio J Juncadella, Douglas A Bayliss, Kodi S Ravichandran. Unexpected link between an antibiotic, pannexin channels and apoptosis.
Nature.
2014 Mar; 507(7492):329-34. doi:
10.1038/nature13147. [PMID: 24646995] - Adnan H Mahmood, Gregory A Medley, Jeffrey E Grice, Xin Liu, Michael S Roberts. Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection.
Journal of pharmaceutical and biomedical analysis.
2012 Mar; 62(?):220-3. doi:
10.1016/j.jpba.2012.01.007. [PMID: 22305082] - Patrick J Shaw, Kevin M Beggs, Erica M Sparkenbaugh, Christine M Dugan, Patricia E Ganey, Robert A Roth. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity.
Toxicological sciences : an official journal of the Society of Toxicology.
2009 Oct; 111(2):288-301. doi:
10.1093/toxsci/kfp163. [PMID: 19638433] - Patrick J Shaw, Patricia E Ganey, Robert A Roth. Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.
The Journal of pharmacology and experimental therapeutics.
2009 Jul; 330(1):72-8. doi:
10.1124/jpet.109.151068. [PMID: 19351866] - Patrick J Shaw, Aaron M Fullerton, Michael A Scott, Patricia E Ganey, Robert A Roth. The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability.
Toxicology and applied pharmacology.
2009 May; 236(3):293-300. doi:
10.1016/j.taap.2009.01.018. [PMID: 19367693] - Patrick J Shaw, Patricia E Ganey, Robert A Roth. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure.
The Journal of pharmacology and experimental therapeutics.
2009 Jan; 328(1):62-8. doi:
10.1124/jpet.108.143792. [PMID: 18820134] - Patrick J Shaw, Amy C Ditewig, Jeffrey F Waring, Michael J Liguori, Eric A Blomme, Patricia E Ganey, Robert A Roth. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury.
Toxicological sciences : an official journal of the Society of Toxicology.
2009 Jan; 107(1):270-80. doi:
10.1093/toxsci/kfn205. [PMID: 18930950] - Patrick J Shaw, Marie J Hopfensperger, Patricia E Ganey, Robert A Roth. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
Toxicological sciences : an official journal of the Society of Toxicology.
2007 Nov; 100(1):259-66. doi:
10.1093/toxsci/kfm218. [PMID: 17709330] - Jeffrey F Waring, Michael J Liguori, James P Luyendyk, Jane F Maddox, Patricia E Ganey, Robert F Stachlewitz, Colin North, Eric A G Blomme, Robert A Roth. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils.
The Journal of pharmacology and experimental therapeutics.
2006 Mar; 316(3):1080-7. doi:
10.1124/jpet.105.096347. [PMID: 16299187] - Laurel C Preheim, Keith M Olsen, Mei Yue, Mary U Snitily, Martha J Gentry-Nielsen. Effect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumonia.
Diagnostic microbiology and infectious disease.
2005 Feb; 51(2):103-11. doi:
10.1016/j.diagmicrobio.2004.09.008. [PMID: 15698715] - Gary E Stein, Sharon Schooley. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
International journal of antimicrobial agents.
2004 Aug; 24(2):168-72. doi:
10.1016/j.ijantimicag.2004.01.013. [PMID: 15288316] - E Azoulay-Dupuis, J P Bédos, J Mohler, G Peytavin, R Isturiz, P Moine, V Rieux, C Cherbuliez, J C Péchère, B Fantin, T Köhler. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Antimicrobial agents and chemotherapy.
2004 Mar; 48(3):765-73. doi:
10.1128/aac.48.3.765-773.2004. [PMID: 14982762] - Irina S Barequet, Paul Denton, Gerard J Osterhout, Suhas Tuli, Terrence P O'Brien. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Archives of ophthalmology (Chicago, Ill. : 1960).
2004 Jan; 122(1):65-9. doi:
10.1001/archopht.122.1.65. [PMID: 14718297] - Archie C Perry, Branko Prpa, Mark S Rouse, Kerryl E Piper, Arlen D Hanssen, James M Steckelberg, Robin Patel. Levofloxacin and trovafloxacin inhibition of experimental fracture-healing.
Clinical orthopaedics and related research.
2003 Sep; ?(414):95-100. doi:
10.1097/01.blo.0000087322.60612.14. [PMID: 12966282] - A Lubasch, S Ziege, B Brodersen, K Borner, P Koeppe, H Lode. Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
2003 Jul; 9(7):670-7. doi:
10.1046/j.1469-0691.2003.00644.x. [PMID: 12925107] - José Luis Vílchez, Jalila Taoufiki, Lilia Araujo, Alberto Navalón. Determination of the antibacterial trovafloxacin by differential-pulse adsorptive stripping voltammetry.
Journal of pharmaceutical and biomedical analysis.
2003 Mar; 31(3):465-71. doi:
10.1016/s0731-7085(02)00713-6. [PMID: 12615233] - Gloria García-Calvo, Araceli Parra, Carmen Ponte, Francisco Soriano, María J Giménez, Lorenzo Aguilar. Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.
International journal of antimicrobial agents.
2002 Dec; 20(6):477-80. doi:
10.1016/s0924-8579(02)00242-x. [PMID: 12458147] - A Calvo, M J Giménez, L Alou, M L Gómez-Lus, L Aguilar, J Prieto. Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.
International journal of antimicrobial agents.
2002 Aug; 20(2):144-6. doi:
10.1016/s0924-8579(02)00119-x. [PMID: 12297365] - P Joyanes, A Pascual, M J Giménez, I García, L Aguilar, E Perea. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
Chemotherapy.
2001 Dec; 47(6):409-14. doi:
10.1159/000048551. [PMID: 11786655] - J Prieto, L Aguilar, F Fuentes, M J Giménez, L Alou, R Dal-Ré, F Sörgel, J Frías. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
International journal of antimicrobial agents.
2001 Sep; 18(3):231-8. doi:
10.1016/s0924-8579(01)00392-2. [PMID: 11673035] - J A Ocaña, M Callejón, F J Barragán. Determination of trovafloxacin in human serum by time resolved terbium-sensitised luminescence.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2001 Jun; 13(3):297-301. doi:
10.1016/s0928-0987(01)00116-6. [PMID: 11384852] - G García-Calvo, A Parra, L Aguilar, C Ponte, M J Giménez, A Carcas, M Kinzig-Schippers, F Soriano. Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study.
Antimicrobial agents and chemotherapy.
2001 Jun; 45(6):1876-8. doi:
10.1128/aac.45.6.1876-1878.2001. [PMID: 11353641] - L E Stearne, I C Gyssens, W H Goessens, J W Mouton, W J Oyen, J W van der Meer, H A Verbrugh. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Antimicrobial agents and chemotherapy.
2001 May; 45(5):1394-401. doi:
10.1128/aac.45.5.1394-1401.2001. [PMID: 11302801] - F López Fornas, F Martínez García, J Pérez Salmeron, D Roldán Conesa, R Cortés Sanchez, A García Alberola, J Ruíz Gómez, J Gómez Gómez, M Valdés Chávarri. Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy.
2001 May; 47(5):623-9. doi:
10.1093/jac/47.5.623. [PMID: 11328774] - R Thiel, S Metzner, C Gericke, U Rahm, R Stahlmann. Effects of fluoroquinolones on the locomotor activity in rats.
Archives of toxicology.
2001 Mar; 75(1):36-41. doi:
10.1007/s002040000207. [PMID: 11357519] - G Garcia-Calvo, A Molleja, M J Giménez, A Parra, E Nieto, C Ponte, L Aguilar, F Soriano. Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin (200 milligrams) on fecal flora in healthy volunteers.
Antimicrobial agents and chemotherapy.
2001 Feb; 45(2):608-11. doi:
10.1128/aac.45.2.608-611.2001. [PMID: 11158764] - M Purswani, S Eckert, H Arora, R Johann-Liang, G J Noel. The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine mRNA transcription by trovafloxacin.
The Journal of antimicrobial chemotherapy.
2000 Dec; 46(6):921-9. doi:
10.1093/jac/46.6.921. [PMID: 11102411] - A A Khan, T R Slifer, F G Araujo, Y Suzuki, J S Remington. Protection against lipopolysaccharide-induced death by fluoroquinolones.
Antimicrobial agents and chemotherapy.
2000 Nov; 44(11):3169-73. doi:
10.1128/aac.44.11.3169-3173.2000. [PMID: 11036044] - K G Naber, K Hollauer, D Kirchbauer, W Witte. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
International journal of antimicrobial agents.
2000 Nov; 16(3):239-43. doi:
10.1016/s0924-8579(00)00222-3. [PMID: 11091042] - W Ng, K Olsen, I Lutsar, L Wubbel, F Ghaffar, H Jafri, G H McCracken, I R Friedland. Buffy coat PCR for diagnosis of experimental pneumococcal pneumonia.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
2000 Nov; 108(11):729-33. doi:
10.1034/j.1600-0463.2000.d01-21.x. [PMID: 11211965] - J McNabb, R Quintiliani, C H Nightingale, D P Nicolau. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
Chemotherapy.
2000 Nov; 46(6):383-9. doi:
10.1159/000007318. [PMID: 11053903] - P D Holtom, S A Pavkovic, P D Bravos, M J Patzakis, L E Shepherd, B Frenkel. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
2000 Sep; 18(5):721-7. doi:
10.1002/jor.1100180507. [PMID: 11117292] - I Odenholt, T Cars, E Lowdin. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
The Journal of antimicrobial chemotherapy.
2000 Jul; 46(1):35-43. doi:
10.1093/jac/46.1.35. [PMID: 10882686] - S Gollapudi, S Gupta, H Thadepalli. Salmonella typhimurium-induced reactivation of latent HIV-1 in promonocytic U1 cells is inhibited by trovafloxacin.
International journal of molecular medicine.
2000 Jun; 5(6):615-8. doi:
10.3892/ijmm.5.6.615. [PMID: 10812011] - J S Bradley, G L Kearns, M D Reed, E V Capparelli, J Vincent. Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
Antimicrobial agents and chemotherapy.
2000 May; 44(5):1195-9. doi:
10.1128/aac.44.5.1195-1199.2000. [PMID: 10770751] - D E King, R Malone, S H Lilley. New classification and update on the quinolone antibiotics.
American family physician.
2000 May; 61(9):2741-8. doi:
NULL. [PMID: 10821154] - E J Giamarellou-Bourboulis, H Sambatakou, P Grecka, Z Chryssouli, H Giamarellou. Sitafloxacin (DU-6859a) and trovafloxacin: postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus.
Diagnostic microbiology and infectious disease.
1999 Aug; 34(4):301-7. doi:
10.1016/s0732-8893(99)00044-9. [PMID: 10459481] - K Goel, D Menzies, B A Cunha. Elevated international normalized ratio associated with trovafloxacin.
Annals of internal medicine.
1999 Jul; 131(1):72. doi:
10.7326/0003-4819-131-1-199907060-00024. [PMID: 10391825] - L Alou, M L Anta, M G Del Potro, F Fuentes, I P Balcabao, M L Gomez-Lus, J Prieto. Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection.
International journal of antimicrobial agents.
1999 Jul; 12(2):135-9. doi:
10.1016/s0924-8579(99)00062-x. [PMID: 10418758] - G W Amsden, D M Graci, L J Cabelus, L G Hejmanowski. A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections.
Chest.
1999 Jul; 116(1):115-9. doi:
10.1378/chest.116.1.115. [PMID: 10424513] - K Borner, H Hartwig, H Lode. Determination of trovafloxacin in human body fluids by high-performance liquid chromatography.
Journal of chromatography. A.
1999 Jun; 846(1-2):175-80. doi:
10.1016/s0021-9673(99)00247-2. [PMID: 10420609] - W Ng, I Lutsar, L Wubbel, F Ghaffar, H Jafri, G H McCracken, I R Friedland. Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
The Journal of antimicrobial chemotherapy.
1999 Jun; 43(6):811-6. doi:
10.1093/jac/43.6.811. [PMID: 10404320] - P D Lister, C C Sanders. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Antimicrobial agents and chemotherapy.
1999 May; 43(5):1118-23. doi:
10.1128/aac.43.5.1118. [PMID: 10223923] - C C McCoig, L Wubbel, H S Jafri, I Lutsar, R Bastero, K Olsen, S Shelton, I R Friedland, G H McCracken. Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis.
The Journal of antimicrobial chemotherapy.
1999 May; 43(5):683-8. doi:
10.1093/jac/43.5.683. [PMID: 10382890] - L C Preheim, K M Olsen, M Yue, M U Snitily, M J Gentry. Ethanol feeding does not affect the efficacy or pharmacokinetics of azithromycin, trovafloxacin, or ceftriaxone in a rat model of pneumococcal pneumonia.
Alcoholism, clinical and experimental research.
1999 May; 23(5):842-9. doi:
. [PMID: 10371404] - E B Breitschwerdt, M G Papich, B C Hegarty, B Gilger, S I Hancock, M G Davidson. Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs.
Antimicrobial agents and chemotherapy.
1999 Apr; 43(4):813-21. doi:
10.1128/aac.43.4.813. [PMID: 10103185] - A A Alghasham, M C Nahata. Trovafloxacin: a new fluoroquinolone.
The Annals of pharmacotherapy.
1999 Jan; 33(1):48-60. doi:
10.1345/aph.17460. [PMID: 9972385] - G Melnik, W H Schwesinger, L C Dogolo, R Teng, J Vincent. Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery.
American journal of surgery.
1998 Dec; 176(6A Suppl):14S-17S. doi:
10.1016/s0002-9610(98)00214-1. [PMID: 9935251] - M G Martens, M Maccato, C Van Hook, J Vincent. Penetration of trovafloxacin into gynecologic tissues.
American journal of surgery.
1998 Dec; 176(6A Suppl):18S-22S. doi:
10.1016/s0002-9610(98)00215-3. [PMID: 9935252] - J Vincent, R Teng, S M Pelletier, S A Willavize, H L Friedman. The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
American journal of surgery.
1998 Dec; 176(6A Suppl):23S-26S. doi:
10.1016/s0002-9610(98)00216-5. [PMID: 9935253] - A B Onderdonk. Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.
American journal of surgery.
1998 Dec; 176(6A Suppl):39S-45S. doi:
10.1016/s0002-9610(98)00219-0. [PMID: 9935256] - C H van Nispen, A I Hoepelman, M Rozenberg-Arska, J Verhoef, L Purkins, S A Willavize. A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers.
American journal of surgery.
1998 Dec; 176(6A Suppl):27S-31S. doi:
10.1016/s0002-9610(98)00217-7. [PMID: 9935254] - J Vincent, T Hunt, R Teng, L Robarge, S A Willavize, H L Friedman. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects.
American journal of surgery.
1998 Dec; 176(6A Suppl):32S-38S. doi:
10.1016/s0002-9610(98)00218-9. [PMID: 9935255] - J Vincent, R Teng, D K Dalvie, H L Friedman. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
American journal of surgery.
1998 Dec; 176(6A Suppl):8S-13S. doi:
10.1016/s0002-9610(98)00213-x. [PMID: 9935250] - A J Fischman, J W Babich, A A Bonab, N M Alpert, J Vincent, R J Callahan, J A Correia, R H Rubin. Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.
Antimicrobial agents and chemotherapy.
1998 Aug; 42(8):2048-54. doi:
10.1128/aac.42.8.2048. [PMID: 9687405] - E W Ng, N Samiy, K L Ruoff, F V Cousins, D C Hooper, S von Gunten, D J D'Amico, A S Baker. Treatment of experimental Staphylococcus epidermidis endophthalmitis with oral trovafloxacin.
American journal of ophthalmology.
1998 Aug; 126(2):278-87. doi:
10.1016/s0002-9394(98)00157-3. [PMID: 9727522] - G Melnik, W H Schwesinger, R Teng, L C Dogolo, J Vincent. Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
1998 Jun; 17(6):424-6. doi:
10.1007/bf01691576. [PMID: 9758286] - L Purkins, S D Oliver, S A Willavize. An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
1998 Jun; 17(6):431-3. doi:
10.1007/bf01691578. [PMID: 9758288] - J Vincent, L Dogolo, B A Baris, S A Willavize, R Teng. Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
1998 Jun; 17(6):427-30. doi:
10.1007/bf01691577. [PMID: 9758287] - J P Bédos, V Rieux, J Bauchet, M Muffat-Joly, C Carbon, E Azoulay-Dupuis. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Antimicrobial agents and chemotherapy.
1998 Apr; 42(4):862-7. doi:
10.1128/aac.42.4.862. [PMID: 9559797] - J Z Montgomerie, D G Schick. Treatment of enterococcal pyelonephritis with trovafloxacin and rifampin: in vitro-in vivo contrast.
Antimicrobial agents and chemotherapy.
1998 Jan; 42(1):188-9. doi:
10.1128/aac.42.1.188. [PMID: 9449285] - H Thadepalli, S K Chuah, U Reddy, N Hanna, R Clark, R J Polzer, S Gollapudi. Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.
Antimicrobial agents and chemotherapy.
1997 Sep; 41(9):1933-6. doi:
10.1128/aac.41.9.1933. [PMID: 9303387] - J Vincent, R Teng, L C Dogolo, S A Willavize, H L Friedman. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers.
The Journal of antimicrobial chemotherapy.
1997 Jun; 39 Suppl B(?):81-6. doi:
10.1093/jac/39.suppl_2.81. [PMID: 9222075] - R Teng, L C Dogolo, S A Willavize, H L Friedman, J Vincent. Oral bioavailability of trovafloxacin with and without food in healthy volunteers.
The Journal of antimicrobial chemotherapy.
1997 Jun; 39 Suppl B(?):87-92. doi:
10.1093/jac/39.suppl_2.87. [PMID: 9222076] - J Vincent, J Venitz, R Teng, B A Baris, S A Willavize, R J Polzer, H L Friedman. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
The Journal of antimicrobial chemotherapy.
1997 Jun; 39 Suppl B(?):75-80. doi:
10.1093/jac/39.suppl_2.75. [PMID: 9222074] - N R Cutler, J Vincent, S S Jhee, R Teng, T Wardle, G Lucas, L C Dogolo, J J Sramek. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.
Antimicrobial agents and chemotherapy.
1997 Jun; 41(6):1298-300. doi:
10.1128/aac.41.6.1298. [PMID: 9174187] - J M Andrews, D Honeybourne, N P Brenwald, D Bannerjee, M Iredale, B Cunningham, R Wise. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy.
The Journal of antimicrobial chemotherapy.
1997 Jun; 39(6):797-802. doi:
10.1093/jac/39.6.797. [PMID: 9222050] - D K Dalvie, N Khosla, J Vincent. Excretion and metabolism of trovafloxacin in humans.
Drug metabolism and disposition: the biological fate of chemicals.
1997 Apr; 25(4):423-7. doi:
NULL. [PMID: 9107540] - H Thadepalli, U Reddy, S K Chuah, F Thadepalli, C Malilay, R J Polzer, N Hanna, A Esfandiari, P Brown, S Gollapudi. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Antimicrobial agents and chemotherapy.
1997 Mar; 41(3):583-6. doi:
10.1128/aac.41.3.583. [PMID: 9055997] - G R Dickens, D Wermeling, J Vincent. Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men.
Journal of clinical pharmacology.
1997 Mar; 37(3):248-52. doi:
10.1002/j.1552-4604.1997.tb04787.x. [PMID: 9089427] - J W Babich, R H Rubin, W A Graham, R A Wilkinson, J Vincent, A J Fischman. 18F-labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP 99,219).
Nuclear medicine and biology.
1996 Nov; 23(8):995-8. doi:
10.1016/s0969-8051(96)00153-9. [PMID: 9004287] - D K Dalvie, N B Khosla, K A Navetta, K E Brighty. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways.
Drug metabolism and disposition: the biological fate of chemicals.
1996 Nov; 24(11):1231-40. doi:
NULL. [PMID: 8937858] - R Teng, T E Liston, S C Harris. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.
The Journal of antimicrobial chemotherapy.
1996 May; 37(5):955-63. doi:
10.1093/jac/37.5.955. [PMID: 8737145] - R Teng, D Girard, T D Gootz, G Foulds, T E Liston. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.
Antimicrobial agents and chemotherapy.
1996 Mar; 40(3):561-6. doi:
10.1128/aac.40.3.561. [PMID: 8851571] - P H Edelstein, M A Edelstein, J Ren, R Polzer, R P Gladue. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.
Antimicrobial agents and chemotherapy.
1996 Feb; 40(2):314-19. doi:
10.1128/aac.40.2.314. [PMID: 8834872] - R Teng, T G Tensfeldt, T E Liston, G Foulds. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications.
1996 Jan; 675(1):53-9. doi:
10.1016/0378-4347(95)00340-1. [PMID: 8634768] - R Wise, D Mortiboy, J Child, J M Andrews. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
Antimicrobial agents and chemotherapy.
1996 Jan; 40(1):47-9. doi:
10.1128/aac.40.1.47. [PMID: 8787877] - A E Girard, D Girard, T D Gootz, J A Faiella, C R Cimochowski. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Antimicrobial agents and chemotherapy.
1995 Oct; 39(10):2210-6. doi:
10.1128/aac.39.10.2210. [PMID: 8619569] - R Teng, S C Harris, D E Nix, J J Schentag, G Foulds, T E Liston. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
The Journal of antimicrobial chemotherapy.
1995 Aug; 36(2):385-94. doi:
10.1093/jac/36.2.385. [PMID: 8522468] - M M París, S M Hickey, M Trujillo, S Shelton, G H McCracken. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.
Antimicrobial agents and chemotherapy.
1995 Jun; 39(6):1243-6. doi:
10.1128/aac.39.6.1243. [PMID: 7574509]